Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...
Summit Therapeutics (SMMT) boost Instil Bio (TIL) and BioNTech (BNTX) as its PD-1/VEGF bispecific antibody outperforms ...
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...
The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Zacks.com on MSN7d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback